Activation of tumor necrosis factor receptor-1 can trigger survival or apoptosis pathways. In many cellular models, including the neuronal cell model PC12, it has been demonstrated that inhibition of protein synthesis is sufficient to render cells sensitive to apoptosis induced by TNFa. The survival effect is linked to the translocation of the transcription factor nuclear factor-kappa B (NF-jB) to the nucleus and activation of survival-related genes such as FLICE-like inhibitory protein long form (FLIP-L) or IAPs. Nonetheless, we previously reported an NF-jB-independent contribution of Bcl-xL to cell survival after TNFa treatment. Here, we demonstrate that NF-jB-induced increase in FLIP-L expression levels is essential for mitogen-activated protein kinases/ extracellular signal-regulated kinases (MAPK/ERK) activation. We demonstrate that FLIP-L behaves as a Raf-1 activator through both protein-protein interaction and Raf-1 kinase activation, without the requirement of the classical Ras activation. Importantly, prevention of FLIP-L increase by NF-jB inhibition or knockdown of endogenous FLIP-L blocks MAPK/ERK activation after TNFa treatment. From a functional point of view, we show that inhibition of the MAPK/ERK pathway and the NF-jB pathway are equally relevant to render PC12 cells sensitive to cell death induced by TNFa. Apoptosis induced by TNFa under these conditions is dependent on jun nuclear kinase1/2 JNK1/2-dependent Bim upregulation. Therefore, we report a previously undescribed and essential role for MAPK/ERK activation by FLIP-L in the decision between cell survival and apoptosis upon TNFa stimulation.
Subject Category: Cancer
Death receptors (DR) are members of the tumor necrosis factor (TNF) superfamily that comprise in their cytosolic tail a death domain able to initiate a signal transduction cascade ultimately leading to apoptosis. 1 DRs and their ligands are expressed under physiological conditions in a variety of tissues including the nervous system, especially during development. [2] [3] [4] [5] [6] However, most neurons express DRs without being sensitive to DR-mediated apoptosis. Indeed, activation of DRs also conveys alternative, non-apoptotic signaling pathways involved in cell survival, differentiation, 7 or the control of inflammatory and immune responses.
The binding of TNF-alpha (TNFa) to its receptor tumor necrosis factor receptor-1 (TNFR1) can alternatively induce cell death or survival and differentiation through the formation of two sequential complexes. 9 While complex I triggers rapid activation of the transcription factors nuclear factor-kappa B (NF-kB) and activator protein-1, Complex II is formed after the former is released from the membrane into the cytosol by receptor internalization and endosomal trafficking. 10, 11 Complex II leads to the death-inducing signaling complex formation and ultimately, caspase-dependent apoptosis. NF-kB activation following DR stimulation leads to the transcriptional activation of pro-survival genes, such as those encoding for inhibitor of apoptosis proteins cIAP1/2, Bcl-2, BclxL or cellular FLICE-like inhibitory protein. 12 NF-kB activation has been considered as the main pathway leading to differentiation and survival effects induced by TNFa. 13, 14 When NF-kB is activated after complex I formation, FLIP-L translocates to complex II in order to prevent caspase-8 activation. However, when NF-kB activation is impaired or when de novo protein synthesis is blocked, TNFa induces apoptotic cell death. 7, 15, 16 Several targets of NF-kB, such as cFLIP, 13 cIAP1/2 17 and in some models, antiapoptotic Bcl-2 family proteins such as Bcl-2 18 , A1 19 or Bcl-xL 20 have been proposed as regulators of TNFa-induced apoptosis. We have recently demonstrated that Bcl-xL regulates TNFa-induced cell death, independently of NF-kB or cFLIP. 15 However, the mechanisms through which inhibition of NF-kB or cFLIP sensitizes cells to TNFa-induced apoptosis remain largely unknown. FLIP-L protects from DR-induced apoptosis in a wide range of cellular models. [21] [22] [23] While the antiapoptotic role of FLIP-L is well established in the immune system, [24] [25] [26] only a couple of reports have shown that FLIP-L controls embryonic motoneurons apoptosis during development 27 and protects neurons against in vivo ischemia and in vitro glucose deprivation-induced cell death. 28 We have recently established that FLIP-L is crucial for neurotrophin-induced neurite outgrowth through its interaction with Trk receptors, inducing the activation of both NF-kB and mitogen-activated protein kinases/extracellular signal-regulated kinases (MAPK/ERK) pathways. 29 We also demonstrated that FLIP-L function in neurotrophin-induced differentiation is independent from its antiapoptotic role. However, the relevance of the MAPK/ERK and NF-kB pathways in the antiapoptotic function of FLIP-L in the nervous system has never been addressed before. It has been suggested that DRs can also induce activation of MAPK/ ERK pathway and jun nuclear kinase (JNK), [30] [31] [32] [33] even though the mediators of this activation and its biological role remain controversial. Therefore, we sought to determine the role of FLIP-L in DR-induced survival and apoptotic pathway.
We show here that TNFa treatment induces apoptosis when either NF-kB or MAPK/ERK pathway is blocked. Otherwise, TNFa treatment induces the activation of the MAPK/ERK pathway that depends on the specific regulation of FLIP-L transcription by NF-kB. FLIP-L interacts with Raf-1 and induces the activation of MAPK/ERK that is due to Raf-1 kinase activation but not Ras activation. We further demonstrate that MAPK/ERK is an important regulator of TNFa-induced cell death in a neuronal cell model, as rescuing its activation by a constitutively active form of MEK or NGF treatment protects from TNFa-induced apoptosis. Finally, we point out the relevance of the JNK pathway and the proapoptotic BH3-only protein Bim in TNFa-induced apoptotic response. Therefore, our findings suggest a novel mechanism for TNFa-mediated neuroprotection versus cell death mechanism.
Results NF-jB inhibition sensitizes PC12 cells to the apoptotic effect of TNFa. NF-kB has been postulated, in many cellular models, to be the main regulator of the antiapoptotic response triggered by TNFR1 activation. To confirm that NF-kB inhibition sensitizes PC12 cells to apoptosis induced by TNFa, we stably transfected PC12 cells with an empty plasmid or a non-degradable form of human IkBa (S32A/ S36A), named SR-IkBa, which blocks TNFa-induced NF-kB activation. Cells were untreated or treated with TNFa for different time points and executioner caspase activity was analyzed (Figure 1a) , showing a gradual increase in caspase activity induced by TNFa that was significant only when NF-kB activation has been blocked. As maximal caspase activation is reached after 24 h of TNFa treatment, cell death was determined by counting of apoptotic nuclei at the same time point (Figure 1b) , revealing that PC12 cells overexpressing the super-repressor (SR-IkBa) plasmid and treated with TNFa undergo apoptosis when compared with cells expressing the control plasmid (Neo). Moreover, TNFainduced 3 0 -OH DNA labeled ends (TUNEL) is only seen in PC12 cells transfected with the SR-IkBa (Figure 1c ). Efficient blockade of NF-kB activation is controlled by the inhibition of the nuclear translocation of p65 in SR-IkBa-transfected cells treated with TNFa for 15 min (Figures 1d and 1e) , as well as the accurate expression of the SR-IkBa mutant form of human IkBa by western blotting (Figure 1f ).
NF-jB-induced FLIP-L expression controls MAPK/ERK activation. Although it has been previously reported that DRs can activate the MAPK/ERK pathway, the mechanism and relevance of DR-induced MAPK activation in the nervous system remain unknown. 9, 30, 34, 35 In order to assess the activation of MAPK/ERK by TNFa, we first analyzed the timecourse and dose-dependence of ERK1/2 activation by TNFa treatment. TNFa induces a rapid phosphorylation of ERK1/2 that is maximal at 5 min and decreases later on until it is almost undetectable after 60 min of treatment ( Figure 2a) . Moreover, increasing concentrations of TNFa have the same effect on TNFa-induced MAPK/ERK activation after 5 min of treatment ( Figure 2b ). In the immune system, it has been shown that MAPK activation by Fas treatment is dependent on FLIP-L. 24 As FLIP-L is one of the genes regulated by NF-kB in many cells, we explored the putative role of NF-kB in FLIP-L expression and the role of FLIP-L in MAPK/ERK activation. Transient transfection of PC12 cells with an empty pcDNA3 plasmid (Neo) or with the SR-IkBa shows that NF-kB regulates FLIP-L expression as it decreases over time until it is almost undetectable after 2 days of SR-IkBa transfection. However, the expression of Bcl-xL remains unchanged (Figure 2c TNFa induces FLIP-L-dependent Raf-1 activation. As we demonstrate here that FLIP-L is necessary for TNFa-induced MAPK activation, we further analyzed the upstream step that is critical for this event. ERK1/2 activation is frequently a result of Ras activation, which recruits to the membrane the TNFa activates MAPK/ERK through FLIP-L F Marques-Fernandez et al MAPKKK Raf-1, leading to the activation of the MAPKK MEK1 that in turn phosphorylates ERK1/2. 36 We show that TNFa treatment, unlike NGF treatment, does not activate Ras, the protein upstream Raf-1 in the MAPK pathway, as seen by pull-down of active Ras (Figure 3a) . However, a Raf-1 kinase assay performed in PC12 cells treated with TNFa or NGF for 5 min reveals Raf-1 activation (Figure 3b ). Moreover, we show that TNFa-induced Raf-1 activation, as well as ERK1/2 phosphorylation depends on NF-kB activity, because Raf-1 is inactive in SR-IkB-transfected cells treated with TNFa ( Figure 3c ). In the same manner, FLIP-L knockdown abrogates TNFa-induced Raf-1 activation and subsequent ERK1/2 activation (Figure 3d ), which demonstrates a direct role of FLIP-L in Raf-1 activation and subsequent ERK1/2 phosphorylation. Additionally, we assessed Raf-1 activation by its recruitment to the membrane, as this has been shown to be a main step for Raf-1 activation. A subfractionation analysis reveals that Raf-1 is clearly enriched in membrane fractions in cells treated with TNFa for 15 min, in comparison with a treatment of 5 min or untreated cells (Figure 3e ). We also show that most of the phosphorylated ERK1/2 is located in the cytosol ( Figure 3e ).
As it is well established, we also demonstrate that Raf-1 activation is necessary for MAPK/ERK pathway activation, as Raf-1 knockdown significantly impairs TNFa-induced ERK1/2 phosphorylation ( Figure 3f ). Finally, we show that Raf-1 and FLIP-L interact by immunoprecipitation of FLIP-L in PC12 cells transfected with HA-tagged FLIP-L and/or Raf-1 (Figure 3g ), as a suggestion of a structural basis for Raf-1 activation. Taken together, these results allow us to conclude that FLIP-L is able to activate Raf-1 by an alternative mechanism to the classical Ras activation.
NF-jB and MAPK/ERK inhibition are equivalent for sensitization of PC12 cells to the apoptotic effect of TNFa. As shown in Figure 1 , when NF-kB pathway is blocked, TNFa induces apoptosis. As we have linked NF-kB activation and FLIP-L regulation to MAPK/ERK activation, we further investigated whether inhibition of MAPK/ERK is equivalent to NF-kB blockade in terms of sensitivity to TNFa-induced apoptosis. To this end, we analyzed the effects of TNFa in presence of the MEK1 inhibitor PD98059. (Figure 1b) . Figure 4d shows representative images of nuclear staining with Hoechst 33258 for all treatment conditions. These results allow us to conclude that the inhibition of the MAPK pathway, as well as NF-kB pathway abrogation, sensitizes cells to the pro-apoptotic function of TNFa.
MAPK/ERK activation is essential in the cell survival pathway elicited after TNFa treatment. To further assess the link between NF-kB and MAPK/ERK pathways, we checked whether sustained activation of the MAPK pathway in SR-IkB-expressing cells would protect them from TNFa-induced cell death. Neo-or SR-IkBa-expressing PC12 cells were transfected with a plasmid encoding the constitutively active form of MEK (MEK-CA) or pcDNA3. Figure 5a shows a significant increase in DEVDase activity after 24 h of TNFa treatment in cells expressing SR-IkBa, which is restored to control levels when MEK-CA is coexpressed with the IkBa mutant. In the same sense, apoptotic cell death was quantified by chromatin condensation and we show that the TNFainduced cell death in SR-IkB-expressing cells is significantly reduced to the same level as untreated controls, when both SR-IkBa and MEK-CA are coexpressed (Figure 5b ). PC12 cells transfected with the MEK-CA show constitutive phosphorylation of ERK1/2 as compared with Neo-transfected cells (Figure 5c) . Alternatively, to demonstrate that the activation of MAPK/ERK is essential for neuroprotection upon TNFa treatment, we treated stably transfected Neo and SR-IkB PC12 cells with TNFa, in the presence or not of 100 ng/ml of NGF for 24 h. NGF is a neurotrophin that activates MAPK/ERK through tyrosine kinase receptors by a classical Ras-dependent manner ( Figure 3a) . As evidenced in Figure 5d , TNFa treatment induces apoptosis when the NF-kB pathway is blocked, as compared with Neo control cells. Interestingly, cotreatment with NGF protects these cells from apoptosis induced by TNFa, even though the NF-kB pathway is blocked (Figures 5d and 5e ). These results support that the MAPK/ ERK pathway activation is necessary and sufficient for the pro-survival effects of TNFa. (Figure 6c) . Similarly, we characterized the apoptotic pathway induced by TNFa in PC12 cells in which both JNK1/2 and ERK1/2 phosphorylation is inhibited. PC12 cells treated as in Figure 6c were also pretreated or not with PD98059. The inhibition of the JNK pathway is able to rescue PC12 cells from TNFa-induced apoptosis when the MAPK/ERK pathway has also been blocked (Figure 6d ). Finally, we show that the inhibition of the MAPK/ERK pathway by PD98059 leads to a sustained JNK1/2 phosphorylation and the upregulation of Bim as compared with cells treated with TNFa alone (Figure 6e) , and in a similar manner to NF-kB inhibition (Figure 6a) . Also, the simultaneous inhibition of the MAPK/ERK and the JNK pathway inhibits TNFa-induced Bim upregulation (Figure 6e ). Altogether, our results demonstrate that TNFa induces apoptosis when either NF-kB or the MAPK/ERK pathway is inhibited, and in both cases through the upregulation of the BH3-only protein Bim, which is under the control of JNK1/2 activation.
Discussion
In the present work, we describe the regulation of MAPK/ERK activation by TNFa in the neuronal PC12 cells. Our results suggest a signaling pathway triggered by TNFa and dependent on the regulation of FLIP-L by NF-kB. Moreover, we demonstrate that TNFa-induced MAPK/ERK activation protects PC12 cells from apoptosis. Inhibition of MAPK/ERK pathway or NF-kB pathway renders cells sensitive to TNFainduced apoptosis through a pathway dependent on JNK1/2 phosphorylation. Therefore NF-kB has a crucial role in blocking the apoptotic signaling induced by TNFa. Although the role of NF-kB as a regulator of cell survival, inflammation and immune response has been described extensively, 14, 43 its function in the nervous system remains controversial. While some studies have shown the importance of NF-kB in neuronal death, 44 others using a reporter gene have demonstrated that constitutive NF-kB activation is necessary for neuronal survival during development and in the adult brain. 45 However, the stimuli that contribute to constitutive activation of NF-kB or the mechanism through which it promotes neuronal survival are unclear. In PC12 cells, the NF-kBinducing kinase has been shown to induce cell differentiation and prevent apoptosis, inducing the activation of both IkBa and MAPK. 46 These results support our observations in the same cellular model where TNFa induces ERK1/2 phosphorylation to promote cell survival. In our model, the activation of NF-kB by TNFa stimulation controls FLIP-L but not Bcl-xL expression. 15 Moreover, through a loss-of-function approach, we show that FLIP-L is essential for TNFa-induced MAPK activation. Therefore, our results point to FLIP-L as the key regulator of this activation, linking the pro-survival function of NF-kB to the antiapoptotic role of FLIP-L. Supporting these observations, in a cellular model of lymphocytes, Kataoka et al. 24 have previously demonstrated that activation of Fas by its specific ligand FasL promotes activation of NF-kB and ERK signaling pathways through the interaction of FLIP-L with Raf-1. We also report here the interaction of FLIP-L with Raf-1 in PC12 cells and Raf-1 activation after TNFa stimulation, which ultimately leads to the activation of ERK1/ 2, without the upstream activation of Ras. Even though the interaction of FLIP-L with Raf-1 has been previously reported in different non-neuronal paradigms, it has never been linked to upstream Ras activation. 47, 48 Most importantly, we show that TNFa-induced NF-kB activation, as well as FLIP-L and Raf-1 endogenous levels is essential for the activation of the MAPK/ERK pathway. Additional work is required to elucidate the detailed mechanistics of Raf-1 activation through its interaction with FLIP-L.
We have provided evidence for the role of MAPK/ERK as an inhibitor of TNFa-induced apoptosis, as the constitutively active form of MEK rescues from apoptosis and treatment with a specific inhibitor of the MAPK/ERK pathway is able to sensitize cells to death induced by TNFa. Moreover, characterization of this apoptotic pathway has shown that it is very similar to the one observed when NF-kB activation is blocked, thus further confirming the link between the NF-kB pathway and the MAPK/ERK pathway. JNK1/2 seems to have a relevant role in the apoptotic pathway induced by TNFa when NF-kB is blocked or when the MAPK/ERK pathway is inhibited. It has been established that TNFa induces JNK1/2 activation, which can be repressed by NF-kB through the transcriptional regulation of gadd45bref. 37. When NF-kB activation is impaired, TNFa-induced JNK1/2 activation is maintained, inducing apoptotic cell death. 31, 39 However, the molecular mechanism through which prolonged JNK1/2 activation promotes cell death remains elusive. It has been previously reported that the BH3-only protein Bim has a central role in apoptosis induced by sustained JNK1/2 activation. 41, 42 In our model, TNFa induces an increase in Bim expression when NF-kB activation is blocked by expression of the super-repressor of IkBa, or when the MAPK/ERK pathway is inhibited.
On the one hand, we have characterized the molecular players intervening in the apoptotic response that might be triggered upon TNFa stimulation, but only when the NF-kB and/or MAPK pathway is blocked. On the other hand, we confirm the relevance of the MAPK/ERK activation in the TNFa-induced survival decision by rescuing TNFa-induced cell death with the NGF-induced MAPK activation. Our results clearly show that, unlike NGF that activates MAPK/ERK and NF-kB in two different and redundant pathways, 29 TNFa treatment induces NF-kB and MAPK/ERK activation in one unique pathway as blocking either component leads to the same biological response, more specifically JNK-mediated apoptosis. We demonstrate here that the activation of MAPK/ ERK is key for neuroprotection upon TNFa treatment, as apoptotic pathway triggered by NF-kB inhibition in TNFatreated PC12 cells can be rescued by the MAPK/ERK activation induced by NGF stimulation. While the role of MAPK/ERK activation by neurotrophins as mediators of neuronal survival, differentiation and synaptic plasticity has been well characterized, 49 there is little information about the role of MAPK/ERK activation induced by DRs in the nervous system. Desbarats et al. 30 described that Fas is able to induce neurite outgrowth in dorsal root ganglia neurons, through ERK activation and p35 upregulation. The group of Martin-Villalba links the activation of Fas by FasL to glioblastoma invasion mediated by PI3K/AKT and regulated by the Src family protein Yes. 50 The TNF-like weak inducer of apoptosis (TWEAK) has a neuroprotective role in the central nervous system, since treatment with recombinant TWEAK or expression of its receptor Fn14-induced hypoxic and ischemic tolerance through TNFa-induced ERK1/2 activation. 51 Altogether, we present a mechanism through which NF-kB is able to block TNFa-induced apoptosis in a neuronal model. Our results provide an answer to questions related to observations done in the nervous system in which TNFa and other DRs, apart from their well-documented apoptotic role in neurodegenerative diseases, [52] [53] [54] [55] exert a protective role. This role seems relevant in physiological processes such as development of the nervous system, 56 and pathological conditions, such as the protection provided by TNF family molecules after an ischemic insult. 57 In summary, we have uncovered a single activation pathway for MAPK/ERK, regulated by NF-kB through the transcriptional regulation of the classical antiapoptotic protein FLIP-L, and directly involved in the regulation of neuronal death and survival.
Materials and Methods
Reagents. Recombinant human TNFa purchased from Biotrend (Köln, Germany) was used at 100 ng/ml. Purified recombinant NGF was obtained from Alomone (Jerusalem, Israel). PD98059 (2 0 -amino-3 0 -methoxyflavone), SP600125 and fluorogenic caspase substrate Ac-DEVD-afc were purchased from Calbiochem/Merck Biosciences (San Diego, CA, USA). Unless otherwise specified, all biochemical reagents were purchased from Sigma-Aldrich (Barcelona, Spain).
Cell culture. Rat pheochromocytoma PC12 cells were grown in 100 mm culture dishes (Falcon Discovery Labware, BD Biosciences, San Agustin de Guadalix, Spain) in Dulbecco's Modified Eagle Medium supplemented with 6% heat-inactivated fetal bovine serum (FBS) and 6% heat-inactivated horse serum (HS) (Invitrogen, Barcelona, Spain), 10 mM HEPES, 20 U/ml penicillin, and 20 mg/ ml streptomycin. Cultures were maintained at 37 1C in a humidified atmosphere of 95% air and 5% CO 2 . PC12 cells were serum-deprived for 12-16 h prior treatment with TNFa or NGF. When pharmacological inhibitors were used, cells were pretreated with the indicated inhibitor for 30 min prior cotreatment with the given inhibitor and TNFa.
Plasmids. Super-repressor IkBa (SR-IkBa) cDNA was expressed under the control of a cytomegalovirus constitutive promoter in the pcDNA3 expression vector (Invitrogen). FLIP-L-FLAG cDNA was subcloned into the pEIGW vector, giving rise to the lentiviral pEIGW-FLIP-L-FLAG overexpressing construct. For RNA interference experiments, pLVTHM-shFLIP-L and its scrambled control plasmid that has been described and validated by Moubarak et al. 29 were used for lentiviral knockdown experiments.
The Glu217-Glu221 MAPKK1 mutant construct (MEK-CA, constitutively active MAPKK1) was kindly provided by C E Marshall (Institute of Cancer Research, London, United Kingdom) through A López-Rivas (CSIC, Granada, Spain).
Cell transfection and infection. PC12 cells were transfected with the desired plasmid using Lipofectamine 2000 reagent (Invitrogen) following the manufacturer's instructions. PC12 cells stably expressing the super-repressor of IkBa, pcDNA3-SR-IkBa or empty pcDNA3 (Neo) were obtained as described by Sole et al.
58 PC12 were transfected using Dharmafect (Dharmacon, ThermoFischer Scientific, Lafayette, CO, USA) with specific oligonucleotides targeting rat Raf-1, which sequence is as follows:
The siRNA used to silence Raf-1 was designed using the siDESIGN webpage (Thermo Fischer Scientific), and targets the nucleotide in position 414 of the open reading frame of rat Raf-1 (NCBI accession number NM_012639.2). shRNA lentiviral infection was performed when required, in order to assess the effects of FLIP-L knockdown by knockdown strategy or to overexpress FLIP-L. FLIP-L levels were assessed by western blot, and lentiviruses efficiently induced FLIP-L protein overexpression or reduced protein levels after 2 and 3 days of infection, respectively. Lentiviral production. Lentiviruses were produced as described previously by Segura et al.
59
Cell viability assays. For apoptotic nuclear morphology, cells were plated in 24-well plates at 5 Â 10 4 cells/well, cultured for 24 h with complete growth medium and treated for the indicated times. Cells were then fixed with 2% paraformaldehyde and stained with 0.05 mg/ml of Hoechst 33258 for 30 min at room temperature. Condensed or fragmented nuclei (apoptotic nuclear morphology type II) were counted as dead cells as described by Yuste et al. 60 The quantification of cell death by chromatin condensation was performed in blind testing, counting at least 300 cells for each data point, and was repeated at least three times in independent experiments. Apoptosis was also assessed by TUNEL staining. Cells were fixed in 2% paraformaldehyde/PBS for 60 min at room temperature, permeabilized with 0.1% Triton-X-100 0.1% sodium citrate for 20 min at 4 1C and stained following the In situ Cell Death Detection Kit instructions (Roche, Sant Cugat del Vallès, Spain). At the final step, Hoechst 33258 was added at a final concentration of 0.05 mg/ml.
Caspase activity. After the indicated treatments, cells were rinsed once with PBS and resuspended in lysis buffer containing 20 mM HEPES/NaOH pH 7.2, 10% sucrose, 150 mM NaCl, 10 mM DTT, 5 mM EDTA, 1% Nonidet P-40, 0.1% CHAPS and 1 Â EDTA-free complete protease inhibitor cocktail (Roche). Lysates were cleared by centrifugation at 16 000 Â g for 5 min. and supernatant proteins were quantified by the Bradford method. Assays were performed in triplicate using 25 mg of protein in the same specific lysis buffer supplemented with 25 mM of the fluorogenic substrate Ac-DEVD-afc. Plates were read in a fluorimeter using a 360-nm (40 nm bandwidth) excitation filter and a 530-nm (25 nm bandwidth) emission filter. Alternatively, we used the method described by Yuste et al., 60 adding the cell lysis buffer with the fluorogenic substrate directly to the cells in the plate after treatment.
Immunofluorescence of RelA/p65 nuclear translocation. To determine NF-kB activation, we performed an immunofluorescence against p65 to detect its nuclear translocation after treatment with TNFa, as described previously. 58 Raf-1 translocation to the cytoplasmic membrane. The translocation of Raf-1 to the cytoplasmic membrane was determined by subfractionation. PC12 cells treated as indicated were rinsed once with ice-cold PBS 1 Â , pH 7.2 and scraped in subfractionation buffer (10 mM Hepes, pH 7.4, 2 mM EDTA, 1 mM sodium orthovanadate) supplemented with 1 Â EDTA-free Complete protease inhibitor cocktail (Roche) and 1 Â phosphatase inhibitor cocktail 3. Samples were sonicated and nuclei and cell debris were pelleted by centrifugation for 10 min at 800 Â g, 41C. Supernatants were harvested and centrifuged for 80 min at 100 000 Â g, 4 1C. The supernatants were recovered and labeled as cytoplasmic fraction while pellets were solubilized in subfractionation buffer supplemented with Triton-X-100 1%, and incubated at 4 1C for 30 min. This later fraction was labeled as membrane fraction. Laemmli buffer was added and samples were boiled for 5 min at 95 1C prior western blotting.
Western blot. Cells were rinsed once with ice-cold PBS 1 Â , pH 7.2, and lysed in prewarmed (95 1C) 2% SDS/125 mM Tris-pH6.8 lysis buffer. For detection of phosphorylated JNK, cells were rinsed once with ice-cold PBS, pH 7.2 and resuspended in IP lysis buffer composed 20 mM Tris, pH 7.4, 140 mM NaCl, 10% glycerol, 1 mM sodium orthovanadate, 40 mM b-glycerophosphate, 1% NP-40, supplemented with 1 Â EDTA-free complete protease inhibitor cocktail (Roche) and 1 Â phosphatase inhibitor cocktail 3, prior centrifugation at 16 000 Â g, 4 1C and harvesting supernatants. Protein concentration was quantified by a modified Lowry assay (DC protein assay; Bio-Rad, Hercules, CA, USA). The cell lysates obtained (5-30 mg of protein) were resolved by SDS-polyacrylamide gels and transferred onto polyvinylidene difluoride Immobilon-P membranes (Millipore). After blocking with TBS 1 Â À 0.1% Tween-20 containing 5% non-fat dry milk for 1 h at room temperature, membranes were probed with the appropriate primary antibodies, prior incubation for 1 h with the appropriate specific peroxidase-
